Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey

Zack Pemberton-Whiteley, Esther Natalie Oliva, MD, Jan Geissler, Sophie Wintrich, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Tatyana Ionova, PhD Professor, Anne Rosemary Tate, Jennie Bradley

Blood (2019) 134 (Supplement_1): 4785.

https://doi.org/10.1182/blood-2019-128818

Published: 2019

Journal Articles

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Blood (2019) 134 (Supplement_1): 117.

https://doi.org/10.1182/blood-2019-125562

Published: 2019

Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD

Blood (2019) 134 (Supplement_1): 4093.

https://doi.org/10.1182/blood-2019-126369

Published: 2019

Journal Articles

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Blood (2019) 134 (Supplement_1): 4321.

https://doi.org/10.1182/blood-2019-125134

Published: 2019

Journal Articles

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 4322.

https://doi.org/10.1182/blood-2019-124645

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes

Sohan Deshpande, Monica Turner, Michael Byrnes, Christopher Pelligra, Amy Rines-MacEachern, Madhura Chitnis, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Derek Tang, PhD BSPharm, Jessica Morison, Esther Natalie Oliva, MD

Blood (2019) 134 (Supplement_1): 5838.

https://doi.org/10.1182/blood-2019-124300

Published: 2019

Journal Articles

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

Marta Riva, Lara Crucitti, Emanuele Ravano, MD, Michele Nichelatti, PhD, Gianluigi Reda, MD, Cristina Fiamenghi, Roberto Cairoli, Alfredo Molteni, MD

Blood (2018) 132 (Supplement 1): 4375.

https://doi.org/10.1182/blood-2018-99-115283

Published: 2018

Journal Articles

The Real-World Incidence of Relapse in Acute Myeloid Leukemia (AML): A Systematic Literature Review (SLR)

Esther N. Oliva, Jacob Franek, Dipen Patel, Omer Zaidi, Salem Abi Nehme, Antonio M. Almeida

Blood (2018) 132 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2018-99-111839

Published: 2018

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Blood (2018) 132 (Supplement 1): 468.

https://doi.org/10.1182/blood-2018-99-119430

Published: 2018

Journal Articles

Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies

Pushpendra Goswami, PhD MSc, BPharm, Esther Natalie Oliva, MD, Tatyana Ionova, PhD, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2018) 132 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2018-99-117180

Published: 2018

Journal Articles

Impact of AML on Patients' Lives: The Value of HM-PRO Measurements

Esther Natalie Oliva, MD, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Pushpendra Goswami, PhD MSc, BPharm, Tatyana Ionova, PhD

Blood (2018) 132 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2018-99-117600

Published: 2018

Journal Articles

Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

Pushpendra Goswami, PhD MSc, BPharm, Esther Natalie Oliva, MD, Tatyana Ionova, DSc, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2018) 132 (Supplement 1): 2294.

https://doi.org/10.1182/blood-2018-99-117094

Published: 2018

Journal Articles

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, MD, Paula Rodriguez Otero, MD, Sara Bringhen, MD, Stefania Oliva, Axel Nogai, MD, Michel Attal, MD PhD, Philippe Moreau, Dheepak Kanagavel, Thomas F Fitzmaurice, PhD, Junlong Wu, Joaquin Martinez Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 595.

https://doi.org/10.1182/blood-2018-99-111244

Published: 2018

Journal Articles

Assessing Needs for Support in MDS Patients

Esther Natalie Oliva, MD, Raqeebah Agberemi, Sophie Wintrich

Blood (2018) 132 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2018-99-112967

Published: 2018

Journal Articles

A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia

Raphael Itzykson, MD PhD, Jérôme Lambert, MDPhD, Daniela Barbieri, Berengere Gruson, Sylvain Thepot, MD, Thorsten Braun, MD PhD, Norbert Vey, Jacques Delaunay, MD, Laurence Legros, MD PhD, Julie Lejeune, Rosa Sapena, Nathalie Droin, Francoise Porteu, Eric Solary, MD, Pierre Fenaux, MD PhD

Blood (2017) 130 (Supplement 1): 4266.

https://doi.org/10.1182/blood.V130.Suppl_1.4266.4266

Published: 2017

Journal Articles

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, MD PhD, Jeroen Simon Goede, Agnes Guerci-Bresler, Michel Delforge, MDPhD, Esther Natalie Oliva, MD, Jiri Mayer, Prof, MD SCs, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao

Blood (2017) 130 (Supplement 1): 4271.

https://doi.org/10.1182/blood.V130.Suppl_1.4271.4271

Published: 2017

NARROW

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes

Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

The Real-World Incidence of Relapse in Acute Myeloid Leukemia (AML): A Systematic Literature Review (SLR)

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies

Impact of AML on Patients' Lives: The Value of HM-PRO Measurements

Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Assessing Needs for Support in MDS Patients

A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia

An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only